REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (ticker: TZAC) is a clinical-stage biopharmaceutical company operating in the healthcare and pharmaceutical sector following the completion of a SPAC business combination. The company, focused on developing treatments for central nervous system disorders and other therapeutic indications, filed an 8-K with the U.S. Securities and Exchange Commission on December 12, 2024, continuing its post-merger public company reporting obligations. TZAC represents the operating entity that emerged from a blank-check acquisition vehicle, and its ongoing SEC disclosures reflect its active status as a de-SPAC company in the life sciences space. For complete deal history, sponsor details, and filing analytics on TZAC and the broader SPAC market, sign up for full data access on SpacDesk.